Type 2 diabetes is a growing problem for people from South Asia, whose chances of developing the condition are estimated at between four and six times higher than Europeans.
The global pre-diabetes population is three times the size of the current diabetes patient population. A huge increase in prevalence is in store, and the industry is in dire need of better tools to prevent disease progression.
According to a research paper from Frost & Sullivan, 15 new drugs for Type 2 diabetes are in late-stage development (Phase 3 and preregistration). ‘The Type 2 diabetes market continually advances, primarily due to the dominance of obesity,’ noted a Frost & Sullivan analyst. ‘Current studies of this increasingly competitive market are limited in their approach. Among the many trends we see coming, the pharma industry will address the ubiquity of diabetes by a steady stream of new product launches over the next six years.’
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.Featured companies
- Companies:
- Novo Nordisk Pharmatech
- Zydus Cadila
- Frost and Sullivan
- Emcure Pharmaceuticals